CYDY CytoDyn

CytoDyn to Hold Investment Community Conference Call on February 6, 2020

CytoDyn to Hold Investment Community Conference Call on February 6, 2020

VANCOUVER, Washington, Feb. 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer, and Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, will host an investment community conference call to provide a comprehensive update on Company developments. The conference call will focus on, amongst other updates, the following key agenda items:

  • Status of filing the Biologics License Application (BLA) for leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients
  • Update on CytoDyn’s therapeutic indications involving cancer
  • Update on potential use of leronlimab in China to treat the 2019 Novel Coronavirus (2019-nCov)

Date: Thursday, February 6, 2020

Time: 4:00 p.m. ET / 1:00 p.m. PT

Dial-In: 877-407-2986 US / 201-378-4916 International

A live audio webcast may also be accessed via CytoDyn’s corporate website at  under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link:

A replay of the conference call will be available until March 7, 2020. To access the replay, interested parties may dial 877-660-6853 (US) / 201-612-7415 (international) and enter conference identification number 13695017.

CONTACTS:

Media: 

Grace Fotiades

LifeSci Communications



(646) 876-5026



Investors:

Nader Pourhassan, Ph.D.

President & CEO

EN
03/02/2020

Underlying

CYDYCytoDyn

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE
Free
CYDY CYTODYN

December 2025 Letter to Shareholders

December 2025 Letter to Shareholders VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your support, patience, and continued belief in CytoDyn’s (the “Company”) mission. I will remember 2025 as the year in which we first presented our astonishing survival observations and compelling data on the emerging role of leronlimab in solid tumor oncology. This past year has been one of disciplined execution, operational rebuilding, and meaningful scient...

December 16, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metast...

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with leronlimab in combination with or followed by an immune checkpoint inhibitor VANCOUVER, Washington, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, ...

December 8, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Announces Resolution of Class Action Lawsuit

CytoDyn Announces Resolution of Class Action Lawsuit VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC), today announced that it has reached an agreement in principle to resolve the previously disclosed securities class action lawsuit that was initially fil...

December 1, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic...

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium Company to deliver a poster presentation on clinical data demonstrating sustained remissionfollowing immune checkpoint inhibitor therapy with or after leronlimab treatmentin patients with metastatic or locally advanced triple-negative breast cancer VANCOUVER, Washington, Nov. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mono...

November 24, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Secures $30 Million Commitment from Yorkville Advisors

CytoDyn Secures $30 Million Commitment from Yorkville Advisors VANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has secured a $30 million funding commitment from Yorkville Advisors Global. Under the terms of the agreement, CytoDyn...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch